Common name
N-propylformamide
IUPAC name
N-propylformamide
SMILES
C(NC=O)CC
Common name
N-propylformamide
IUPAC name
N-propylformamide
SMILES
C(NC=O)CC
INCHI
InChI=1S/C4H9NO/c1-2-3-5-4-6/h4H,2-3H2,1H3,(H,5,6)
FORMULA
C4H9NO
Common name
N-propylformamide
IUPAC name
N-propylformamide
Molecular weight
87.120
clogP
0.116
clogS
-0.973
Frequency
0.0031
HBond Acceptor
1
HBond Donor
1
Total PolarSurface Area
29.1
Number of Rings
0
Rotatable Bond
2
| Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
|---|---|---|---|---|
| FDBD00006 | Felypressin |
|
Vasoconstrictor Agents; Renal Agents; | For use as an alternative to adrenaline as a localising agent, provided that local ischaemia is not essential. |
| FDBD00135 | Methysergide |
|
Vasoconstrictor Agents; Analgesics; Serotonin Antagonists; Nervous System; Antimigraine Preparations; Ergot Alkaloids; | For the treatment of vascular headache. |
| FDBD00230 | Alfuzosin |
|
Antihypertensive Agents; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Genito Urinary System and Sex Hormones; Drugs Used in Benign Prostatic Hypertrophy; Urological Agents; CYP3A4 Inhibitors; | For the reduction of urinary obstruction and relief of associated manifestations (eg. sensation of incomplete bladder emptying or straining, urgency, interrupted or weak stream) in patients with symptomatic beningn prostatic hyperplasia. |
| FDBD00237 | Methylergometrine |
|
Oxytocics; Genito Urinary System and Sex Hormones; Uterotonics; Ergot Alkaloids; CYP3A4 Inhibitors; | For the prevention and control of excessive bleeding following vaginal childbirth. |
| FDBD00753 | Benzylpenicilloyl Polylysine |
|
Acetamides; | For use as a adjunct in assessing the risk of administering penicillin (benzylpenicillin or penicillin G). |
| FDBD01321 | Maraviroc |
|
Antiinfectives for Systemic Use; Direct Acting Antivirals; Antivirals for Systemic Use; CYP3A4 Inhibitors; CCR5 Receptor Antagonists; | For treatment-experienced adult patients infected with only CCR5-tropic HIV-1 detectable, who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents. |
| FDBD01523 | Roxatidine acetate |
|
Anti-Ulcer Agents; Alimentary Tract and Metabolism; Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord); Drugs for Acid Related Disorders; H2 Antagonists; | For the treatment of disorders of the upper gastro-intestinal region that are due to an excess of hydrochloric acid in the gastric juice, i.e. duodenal ulcers, benign gastric ulcers. Also for prophylaxis of recurrent gastric and duodenal ulcers. |
| FDBD01652 | Cobicistat |
|
Anti-HIV Agents; Antiinfectives for Systemic Use; Direct Acting Antivirals; Antivirals for Systemic Use; Cytochrome P-450 CYP3A Inhibitors; CYP2D6 Inducers; CYP2D6 Inducers (strong); | Cobicistat is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. It is not interchangeable with ritonavir to increase systemic exposure of darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir due to lack of exposure data. The use of cobicistat is not recommended with darunavir 600 mg twice daily, fosamprenavir, saquinavir or tipranavir. Complex or unknown mechanisms of drug interactions preclude extrapolation of ritonavir drug interactions to certain cobicistat interactions. Cobicistat and ritonavir when administered with either atazanavir or darunavir may result in different drug interactions when used with concomitant medications. |
| FDBD02216 | phosglycin |
|
Insecticide | Insecticide |
9 ,
1
| FRAGNAME | PDBID | SIMILIRITY | XSCORE | SMILE | HAC |
|---|---|---|---|---|---|
| 1qkb_ligand_2_50.mol2 | 1qkb | 1 | -6.32 | C(NC=O)C(C)C | 7 |
| 2xye_ligand_2_29.mol2 | 2xye | 1 | -6.29 | C(=O)NCC(C)(C)C | 8 |
| 2f3e_ligand_2_51.mol2 | 2f3e | 1 | -6.23 | C(=O)NCC(C)C | 7 |
| 2g94_ligand_2_143.mol2 | 2g94 | 1 | -6.23 | C(C(C)C)NC=O | 7 |
| 2qzl_ligand_2_77.mol2 | 2qzl | 1 | -6.21 | C(=O)NCC(C)C | 7 |
| 1oth_ligand_3_10.mol2 | 1oth | 1 | -6.18 | CCCNC=O | 6 |
| 1tcw_ligand_2_76.mol2 | 1tcw | 1 | -6.18 | C(NC=O)C(C)C | 7 |
| 2p4j_ligand_2_114.mol2 | 2p4j | 1 | -6.16 | C(=O)NCC(C)C | 7 |
671 ,
68
